For decades, the diagnosis of clinically significant prostate cancer has rested on an uncomfortable compromise.

In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA ...

The U.S. Food and Drug Administration has granted Fast Track designation to Telix Pharmaceuticals’ BiPASS program, which is ...

GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", www.koelis.com), a leader and innovator in MRI-ultrasound fusion guidance for prostate ...

Investigators ran a simulation of a hypothetical group of 65-year-old men who were at risk for the cancer, as indicated by their prostate-specific antigen (PSA) levels. The costs and benefits of ...

A less expensive, more accessible, and comfortable alternative exists for those facing a prostate cancer biopsy, according to findings from a new clinical trial that Yale Urology contributed to.

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

A trial found no meaningful difference in detection of clinically significantly prostate cancer between multiparametric MRI-based and microultrasound-based biopsy techniques.